Fiera Capital Corp Sells 11,842 Shares of Eli Lilly And Co (NYSE:LLY)

Fiera Capital Corp decreased its stake in shares of Eli Lilly And Co (NYSE:LLY) by 44.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,838 shares of the company’s stock after selling 11,842 shares during the period. Fiera Capital Corp’s holdings in Eli Lilly And Co were worth $2,059,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. BlackRock Inc. lifted its position in Eli Lilly And Co by 5.6% during the first quarter. BlackRock Inc. now owns 64,299,477 shares of the company’s stock valued at $8,919,623,000 after purchasing an additional 3,420,265 shares during the period. Capital International Investors increased its holdings in Eli Lilly And Co by 3.6% during the fourth quarter. Capital International Investors now owns 26,055,933 shares of the company’s stock valued at $3,424,531,000 after buying an additional 910,672 shares during the last quarter. FMR LLC increased its holdings in Eli Lilly And Co by 6.7% during the fourth quarter. FMR LLC now owns 14,235,227 shares of the company’s stock valued at $1,870,935,000 after buying an additional 888,413 shares during the last quarter. Geode Capital Management LLC increased its holdings in Eli Lilly And Co by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 12,377,007 shares of the company’s stock valued at $1,623,438,000 after buying an additional 226,620 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in Eli Lilly And Co by 125.9% during the first quarter. Jennison Associates LLC now owns 10,192,052 shares of the company’s stock valued at $1,413,841,000 after buying an additional 5,679,574 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

A number of brokerages have commented on LLY. Goldman Sachs Group raised shares of Eli Lilly And Co from a “buy” rating to a “conviction-buy” rating and set a $168.00 target price for the company in a report on Wednesday, March 11th. Cfra upped their target price on shares of Eli Lilly And Co from $146.00 to $167.00 and gave the company a “hold” rating in a report on Friday, April 24th. Cantor Fitzgerald upped their target price on shares of Eli Lilly And Co from $156.00 to $185.00 and gave the company an “overweight” rating in a report on Friday, April 24th. Mizuho upped their target price on shares of Eli Lilly And Co from $148.00 to $155.00 and gave the company a “buy” rating in a report on Friday, April 24th. Finally, Cowen increased their price objective on shares of Eli Lilly And Co from $145.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $158.64.

LLY opened at $151.16 on Friday. The stock has a market capitalization of $145.65 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.82 and a beta of 0.25. The company has a fifty day moving average of $152.85 and a 200 day moving average of $136.00. Eli Lilly And Co has a fifty-two week low of $101.36 and a fifty-two week high of $164.90. The company has a debt-to-equity ratio of 4.37, a quick ratio of 0.86 and a current ratio of 1.11.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Thursday, April 23rd. The company reported $1.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.48 by $0.27. The company had revenue of $5.86 billion during the quarter, compared to analysts’ expectations of $5.48 billion. Eli Lilly And Co had a net margin of 23.97% and a return on equity of 194.18%. Eli Lilly And Co’s quarterly revenue was up 15.1% on a year-over-year basis. During the same period last year, the company posted $1.33 earnings per share. On average, equities research analysts forecast that Eli Lilly And Co will post 6.81 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a dividend of $0.74 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.96 annualized dividend and a yield of 1.96%. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 49.01%.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Monday, March 30th. The shares were sold at an average price of $139.11, for a total transaction of $29,213,100.00. Following the completion of the transaction, the insider now owns 113,441,468 shares in the company, valued at $15,780,842,613.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Stephen F. Fry sold 14,657 shares of the firm’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $134.30, for a total transaction of $1,968,435.10. Following the completion of the sale, the senior vice president now owns 110,572 shares of the company’s stock, valued at approximately $14,849,819.60. The disclosure for this sale can be found here. Insiders have sold 906,320 shares of company stock valued at $132,984,238 in the last quarter. 0.09% of the stock is owned by company insiders.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: How can investors invest in the S&P/TSX Index?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.